Daily Stock Analysis, GNCA, Genocea Biosciences Inc, priceseries

Genocea Biosciences Inc. Daily Stock Analysis
Stock Information
Open
0.55
Close
0.50
High
0.55
Low
0.50
Previous Close
0.55
Daily Price Gain
-0.05
YTD High
0.66
YTD High Date
Jan 14, 2019
YTD Low
0.31
YTD Low Date
Jan 2, 2019
YTD Price Change
0.08
YTD Gain
19.05%
52 Week High
1.25
52 Week High Date
Mar 9, 2018
52 Week Low
0.28
52 Week Low Date
Dec 31, 2018
52 Week Price Change
-0.48
52 Week Gain
-48.99%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jul 21. 2017
5.05
Jul 31. 2017
5.72
6 Trading Days
13.22%
Link
LONG
Aug 24. 2017
4.27
Sep 14. 2017
5.01
14 Trading Days
17.30%
Link
LONG
Mar 5. 2018
1.03
Mar 20. 2018
1.12
11 Trading Days
8.30%
Link
Company Information
Stock Symbol
GNCA
Exchange
NasdaqGM
Company URL
http://www.genocea.com
Company Phone
617-876-8191
CEO
Chip Clark
Headquarters
Massachusetts
Business Address
100 ACORN PARK DRIVE, CAMBRIDGE, MA 02140
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001457612
About

Genocea Biosciences is a biopharmaceutical company developing T cell-directed vaccines and immunotherapies to treat infectious diseases and cancer. The company uses its proprietary ATLAS™ antigen identification platform to build a pipeline of immunotherapies that currently includes GEN-003, an immunotherapy for genital herpes, and GEN-009, its first neoantigen cancer vaccine, for which an Investigational New Drug application filing is expected by the end of 2017. Genocea Biosciences was founded by Robert Paull and Kevin J. Bitterman on August 16, 2006 and is headquartered in Cambridge, MA.

Description

Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel vaccines and immunotherapies to treat infectious diseases. The company uses its proprietary discovery platform AnTigen Lead Acquisition System to design vaccines and immunotherapies that act through T cell immune responses. Its lead product candidate is GEN-003, a therapeutic vaccine or immunotherapy that is in Phase 2 trial for the treatment of genital herpes infections. The company is also developing GEN-009, which is in pre-clinical stage for the treatment of immuno-oncology-neoantigen; and GEN-007 that is in research stage for the treatment of Epstein-Barr virus. Genocea Biosciences, Inc. was founded in 2006 and is headquartered in Cambridge, Massachusetts.